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Loss of regions of human chromosome arm 10q have been
reported in various malignant tumours including malignant
melanoma, endometrial cancer, pancreatic cancer, prostate cancer,
small-cell lung cancer and malignant brain tumours (Gray et al,
1995; Hahn et al, 1995; Herbst et al, 1995; Peiffer et al, 1995;
Albarosa et al, 1996; Petersen et al, 1997). Recently, one candidate
tumour-suppressor gene was identified at chromosome 10 q, and
named PTEN (phosphatase and tensin homologue deleted on 
chromosome 10) (Li et al, 1997). Furthermore, a second candidate
tumour-suppressor gene slightly more distal on chromosome 10 q,
and named DMBT1 (deleted in malignant brain tumours), was
also reported (Mollenhauer et al, 1997). The lack of DMBT1
mRNA expression and the homozygous deletion of the DMBT1
gene was reported in malignant brain tumours. DMBT1 was
expressed at highest levels in intestinal (and lung) tissue
(Mollenhauer et al, 1997); however, there is little information on
DMBT1 gene expression in human gastrointestinal cancers such
as oesophageal, gastric or colorectal cancers. We, thus, studied the
mRNA expression and the homozygous deletion of this gene in
these common gastrointestinal cancers.
PATIENTS AND METHODS
Paired normal and tumour total RNAs were purified from 43
oesophageal, 40 gastric and 24 colorectal cancers according to
previously described methods (Li et al, 1995; Mori et al, 1995).
There was no family history of cancer in these 107 cases. Of the
oesophageal cancer cases, 41 were squamous cell cancers and two
were small-cell cancers, histologically. All gastric and colorectal
cancers were adenocarcinomas, histologically. cDNA was synthe-
sized as described previously (Mori et al, 1995, 1998). The ampli-
fication of DMBT1 cDNA was performed in a total volume of 
20 ml, which included polymerase chain reaction (PCR) buffer 
(10 mM tris-HCl, pH 8.3, 50 mM potassium chloride, 2 mM magne-
sium chloride), 200 mM dNTP, 0.5 mM each primer and 2.5 U per
100 ml of Taq DNA polymerase (Promega, Madison, WI, USA),
and PCR conditions included an initial denaturation (94°C for 
5 min), 34 cycles of amplification (94°C 1 min, 55°C 1 min,
72°C 1 min 30 s) followed by a final extension for 10 min at 72°C.
We used DMBT1-specific primer sequences according to
Mollenhauer et al (1997). We determined the nucleotide sequence
of this PCR product and confirmed that it was identical to the
expected fragment of DMBT1 cDNA. To ensure that the RNA was
of sufficient purity for reverse transcriptase polymerase chain
reaction (RT-PCR), a PCR assay with primers specific for the gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA was
carried out in each case (Li et al, 1995; Mori et al, 1995). Aliquots
of the PCR-amplified DNA were electrophoresed on 2% agarose
gels containing ethidium bromide. The expression of DMBT1 and
GAPDH was evaluated by computer-assisted image analysis. The
tumour–normal ratio (T/N ratio) of DMBT1 expression was calcu-
lated after correction for that of GAPDH expression.
Homozygous deletions within the DMBT1 gene in the 43
primary oesophageal cancers were studied by using duplex PCR
described by Mollenhauer et al (1997). The primer sequences of
the target gene (g14 fragment; originally isolated as a 330-bp
representational difference analysis fragment of DMBT1) and 
the internal control gene to DMBT1 were also described by
Mollenhauer et al (1997). Aliquots of the duplex PCR-amplified
DNA were electrophoresed on 2% agarose gels containing
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Japanethidium bromide and evaluated by computer-assisted image
analysis. We determined that the nucleotide sequence of the
duplex PCR products was identical to the expected cDNA frag-
ment of the target gene and the internal control gene. In each case
of primary oesophageal cancer, the density ratio of g14/control in
tumour tissue was divided by that in normal tissue, and a value of
less than 0.3 was regarded as homozygous deletion.
The clinical significance of DMBT1 gene expression in
oesophageal cancers was assessed. We compared several clinico-
pathological factors including histological differentiation, depth of
tumour invasion in the wall, venous vessel invasion, lymphatic
vessel invasion, lymph node metastasis, stage of disease, and
prognosis between cases with reduced DMBT1 expression and
those without reduced expression in oesophageal cancer. For
statistical analysis, Fisher’s exact probability test was used.
RESULTS AND DISCUSSION
The RT-PCR results demonstrated that PCR products of the
expected size were obtained from all normal mucosal tissues of 
the oesophagus, stomach and colorectum. Table 1 summarizes the
results. An apparent reduction (T/N ratio was equal or less than
0.1), or no expression of DMBT1 mRNA, was recognized in
tumour tissues compared with paired normal tissues in 23 (53.5%)
out of 43 oesophageal cancer cases, 5 (12.5%) out of 40 gastric
cancer cases, and 4 (16.7%) out of 24 colorectal cancer cases.
Representative results of primary oesophageal cancer are shown in
Figure 1A. These findings show that DMBT1 mRNA expression
was remarkably suppressed in more than half of human
oesophageal cancer tissues and that it was also reduced in several
gastric or colorectal cancer tissues. With respect to the 15 human
oesophageal cancer cell lines, the DMBT1 mRNA expression was
recognized in only three cell lines (TE15, KY150 and KY36) and
not recognized in the other 12 cell lines as shown in Figure 2A. In
the study of Mollenhauer et al (1997), the lack of DMBT1 expres-
sion was confirmed in four out of five (80%) of the brain-tumour
cell lines. The frequency of the lack of mRNA expression was the
same between the brain-tumour cell lines (four out of five) and the
oesophageal cancer cell lines (12 out of 15).
Mollenhauer et al (1997) showed that intragenic homozygous
deletions of the DMBT1 gene were detected in 2 out of 20 medul-
loblastomas and 9 out of 39 glioblastoma multiforme tumours.
Our study demonstrated that 5 (11.6%) of 43 primary cases of
oesophageal cancer and 2 (13.3%) of the 15 cell lines showed a
homozygous deletion within the DMBT1 gene (Table 1, Figures
1B and 2B). In three of these five primary cases (cases 4, 7 and 10
in Figure 1B), the expected fragment of amplified DNA was
absent from tumour tissue, as shown in Figure 1B. In another two
primary cases (cases 11 and 12), the expected fragment was
reduced to less than 0.3 (0.10 in case 11 and 0.22 in case 12) in the
tumour tissue compared with the paired normal tissue, suggesting
a probable homozygous deletion of the DMBT1 gene. The weak
expression might be due to a contamination by normal cells. All
these five primary tumours and two cell lines (TE1 and TE14 in
Figure 2B) showed no expression of DMBT1 mRNA by RT-PCR.
The findings suggest that DMBT1 may act as a tumour-suppressor
gene not only in brain tumours but also in oesophageal, gastric and
colon cancers.
Eighteen of 23 primary oesophageal cancer cases and 10 out of
12 oesophageal cancer cell lines which either lacked or had
reduced expression of DMBT1 mRNA, however, showed no intra-
genic homozygous deletion of this gene. Having tested g14 for
deletion, this does not allow us to conclude that no other DMBT1
deletions occur in the vast majority of the tumours without expres-
sion, other mechanisms may account for the observed effect 
in these cases or cell lines. Frequent loss of heterozygosity at 
10q23–26 in several cancers strongly suggests the presence of a
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Table 1 The lack of DMBT1 mRNA expression and homozygous deletion
of the g14 fragment of the DMBT1 gene
Lack of DMBT1 Homozygous deletion
expression (%) of g14 (%)
Primary oesophageal cancers 23/43 (53.5) 5/43 (11.6)
Oesophageal cancer cell lines 12/15 (80) 2/15 (13.3)
Primary gastric cancers 5/40 (12.5) Not tested
Primary colon cancers 4/24 (16.7) Not tested
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Figure 1 (A) Representative results of DMBT1 expression determined by RT-
PCR in 12 cases of primary oesophageal cancer. T, tumour tissue, and N,
paired normal tissue, in each case. All the normal tissues examined show
detectable DMBT1 expression. A remarkable reduction or lack of DMBT1
expression is evident in many oesophageal cancer tissues. The RT-PCR was
performed according to a previously described method except for the number of
PCR cycles (34 cycles). The size of the PCR product is 950 bp for DMBT1 and
540 bp for GAPDH (internal control). (B) Results of duplex PCR studying the
homozygous deletion of g14 (a fragment of DMBT1) in the same cases of
oesophageal cancer. The upper band (230 bp) is the fragment of g14, and the
lower band (190 bp) is the fragment of the control gene. In each case of primary
oesophageal cancer, the density ratio of g14/control in tumour tissue was
divided by that in normal tissue and the value of less than 0.3 was regarded as
homozygous deletion. The evaluated value is 1.07, 0.74, 0.91, 0, 0.77, 1.06, 0,
0.78. 1.35, 0, 0.10 and 0.22 in cases 1–12 respectively. Homozygous deletion
is recognized in the tumour tissue of cases 4, 7 and 10, and also in cases 11
and 12. The faint upper band in the tumour tissue of cases 11 and 12 may be
due to contamination by normal cells. These five cases showed no expression
of DMBT1 mRNA in tumour tissue as shown in (A)
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Figure 2 (A) DMBT1 expression determined by RT-PCR in 15 oesophageal
cancer cell lines. The expression is noticed only in TE15, KY159 and KY36.
(B) Duplex PCR studying homozygous deletion of the g14 segment of
DMBT1. Homozygous deletion is recognized in TE1 and TE14. A very faint
upper band is seen in KY30, probably suggesting that one allele is lost. No
expression of DMBT1 mRNA is seen in these three cell linestumour-suppressor gene in this region. In fact, loss of heterozy-
gosity of 10 q was recognized in 17% of oesophageal cancers
(Aoki et al, 1994), 17% of colon cancers and 15% of gastric
cancers (Kong et al, 1997). Our study demonstrated that the
percentage was similar to the lack of DMBT1 gene expression 
in colon (17%) and gastric (13%) cancers. Kong et al (1997),
however, reported that the mutation frequency of the PTEN1 gene
that locates at 10q23.3 and near the DMBT1 gene was rare in
colon and gastric cancers. Thus, further studies on loss of
heterozygosity of DMBT1 and mutation analysis of a retained
allele would be necessary to confirm that DMBT1 may be a candi-
date tumour-suppressor gene in these common cancers.
DMBT1 shows homology to the scavenger receptor cysteine-
rich (SRCR) superfamily (Mollenhauer et al, 1997), but its precise
physiological function is still unknown. We, thus, studied the
significance of DMBT1 expression by comparing the cases with
reduced DMBT1 expression and those without reduced expression
in oesophageal cancer. There was, however, no significant differ-
ence in any of the clinicopathological factors between the two
groups (Table 2). Interestingly, the case with reduced expression
had a tendency to show cancer cell invasion into the vascular
vessels, but this did not reach a statistically significant difference.
Reduction of DMBT1 mRNA expression was recognized even in
early-stage disease (stage I of the TNM classification), suggesting
that it could be an early event in the development of oesophageal
cancer. This is in contrast to malignant brain tumours in which
allelic losses were noted in none of ten low-grade astrocytomas
(Mollenhauer et al, 1997). Further detailed search for the biolog-
ical function of this gene is necessary to understand its function as
a postulated tumour-suppressor gene. This will encourage an
understanding of the molecular mechanism of oesophageal cancer,
one that has a poor prognosis.
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Table 2 Expression of DMBT1 mRNA and oesophageal cancers
Expression of DMBT1 mRNA
T/N>0.1 (n=20) T/N≤0.1 (n=23) P-value
Histology ns
Well scc 6 5
Moderately scc 12 11
Poorly scc 2 6
Small-cell cancer 1 1
Depth of tumour invasion ns
Within the wall 6 4
Adventita 14 16
Invading the adjacent organ 0 3
Venous vessel invasion ns
Absent 9 2
Present 11 21
Lymph vessel invasion ns
Absent 3 2
Present 17 21
Lymph node metastasis ns
Absent 4 3
Present 16 20
Stage ns
12 1
21 0
31 1 1 1
46 1 1
scc, squamous cell cancer; ns, not significantly different.